Industry Breakfasts are commercially supported educational activities held on the mornings of the main ASM days.  Content of the breakfast sessions is not endorsed by the ANZSN.  By registering for an industry breakfast you are agreeing to the breakfast host receiving your contact details.

Advances in ADPKD – Otsuka Breakfast Symposium

  • Date: Tuesday 11th September
  • Time: 0700-0750
  • Venue: Meeting Room C3.6, International Convention Centre

Breakfast speakers include:

  • A/Prof Ian Fraser (Chair), on Clinical experience with tolvaptan in ADPKD 
  • Ben Lundie, Principal Scientist at Genome One, on Modern genomics

Breakfast will be provided.  Numbers limited.  

SGLT2 inhibitors current state of play – Boehringer Ingelheim Breakfast Symposium

  • Date: Tuesday 11th September
  • Time: 0700-0750
  • Venue: Meeting Room C3.4+C3.5, International Convention Centre

Breakfast speaker: Prof Mark Thomas

Dr Mark Thomas trained at Sydney Hospital, RPA and Royal North Shore, then worked in a combined clinical-research position at Guy’s Hospital in London for 3 years, before coming to Royal Perth Hospital as a staff nephrologist in 1988.

He has had an active interest in teaching general medicine and nephrology, which has included nurses, dental and medical students (both urban and rural), AMEC candidates, hospital junior staff, FRACP candidates and fellow nephrologists over the years, as well as many GP educational meetings.

He still works full-time at Royal Perth, with a tiny private practice in Kirkman House, and regular visiting nephrology service to remote areas of Western Australia, first to Kalgoorlie, and now Esperance and the isolated aboriginal community of Tjuntjuntjurra in Spinifex country.

His clinical research interests include kidney disease in Aborigines, diabetic nephropathy, polycystic kidney disease, and the highly specialized problems of loin-pain/haematuria syndrome, and Fabry’s disease, where he runs the Statewide Service. He has published several book chapters, 60 peer-reviewed articles and 97 scientific abstracts.


SGLT2 inhibitors current state of play

The glycosurics and incretins have revolutionised diabetic therapy, exposing just how many previous features of diabetes (hunger, weight-gain, heart failure, sudden death) were medication side-effects rather than the result of patients’ lifestyle choices.

The multi-system effects and benefits of modern diabetic therapy now mandate a new unified collaborative management approach, no longer “gluco-centric”.

Plain English patient & pharmacist education is paramount, both for multi-drug “sick-day plans”, as well as safe transition through the tricky first two months of modern therapy, to avoid precipitating urogenital sepsis, DKA or unmasked critical arterial stenoses.

New hard outcome data is arriving all the time, exploring  the benefits in preventing acute and chronic kidney disease, and primary as well as secondary cardiac events.

Please come and share a few tips, tricks & Thoamasisms.

 

Breakfast will be provided.  Numbers limited.  

*Please note the Advances in Advances in ADPKD breakfast and the SGLT2 inhibitors current state of play breakfast run concurrently on Tuesday morning

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd